Optimization of Versatile Oxindoles as Selective PI3Kδ Inhibitors

被引:12
|
作者
Methot, Joey L. [1 ]
Achab, Abdelghani [1 ]
Christopher, Matthew [1 ]
Zhou, Hua [1 ]
McGowan, Meredeth A. [1 ]
Trotter, B. Wesley [1 ]
Fradera, Xavier [2 ]
Lesburg, Charles A. [2 ]
Goldenblatt, Peter [3 ]
Hill, Armetta [3 ]
Chen, Dapeng [4 ]
Otte, Karin M. [4 ]
Augustin, Martin [5 ]
Shah, Sanjiv [3 ]
Katz, Jason D. [1 ]
机构
[1] Merck & Co Inc, Discovery Chem, Boston, MA 02115 USA
[2] Merck & Co Inc, Computat & Struct Chem, Boston, MA 02115 USA
[3] Merck & Co Inc, In Vitro Pharmacol, Boston, MA 02115 USA
[4] Merck & Co Inc, Pharmacokinet Pharmacodynam & Drug Metab, Boston, MA 02115 USA
[5] Proteros Biostruct, D-82152 Martinsried, Germany
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 12期
关键词
PI3K delta inhibitor; PI3K alpha selectivity; oxindole; adenosine uptake; CHRONIC LYMPHOCYTIC-LEUKEMIA; INDUCED VASCULAR INJURY; PI3K INHIBITORS; IN-VITRO; CD69; MECHANISMS; RESPONSES; POTENCY;
D O I
10.1021/acsmedchemlett.0c00441
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The 3,3-disubstituted oxindole moiety is a versatile and rigid three-dimensionally shaped scaffold. When engineered with a purine hinge-binding core, exceptionally selective PI3K delta kinase inhibitors were discovered by exploiting small differences in isoform selectivity pockets. Crystal structures of early lead 2f bound to PI3K delta and PI3K alpha helped rationalize the high selectivity observed with 2f. By attenuating the lypophilicity and metabolic liabilities of an oxindole moiety, we improved the preclinical species PK and solubility and reduced adenosine uptake activity. The excellent potency and kinome selectivity of 7-azaoxindole 4d and spirooxindole 5d, together with a low plasma clearance and good half-life in rat and dog, supported a low once-daily predicted human dose.
引用
收藏
页码:2461 / 2469
页数:9
相关论文
共 50 条
  • [41] From lab to clinic: The discovery and optimization journey of PI3K inhibitors
    Lian, Siyu
    Du, Zhenhua
    Chen, Qingqing
    Xia, Yu
    Miao, Xinxin
    Yu, Weiwei
    Sun, Qian
    Feng, Chong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 277
  • [42] Horizons broaden for PI3Kδ inhibitors
    Kingwell, Katie
    NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (08) : 573 - 573
  • [43] Novel inhibitors of the PI3K family
    Carnero, Amancio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (09) : 1265 - 1277
  • [44] Cardiovascular toxicity of PI3Kα inhibitors
    Sadasivan, Chandu
    Zhabyeyev, Pavel
    Labib, Dina
    White, James A.
    Paterson, D. Ian
    Oudit, Gavin Y.
    CLINICAL SCIENCE, 2020, 134 (19) : 2595 - 2622
  • [45] PI3Kα Inhibitors That Inhibit Metastasis
    Schmidt-Kittler, Oleg
    Zhu, Jiuxiang
    Yang, Jian
    Liu, Guosheng
    Hendricks, William
    Lengauer, Christoph
    Gabelli, Sandra B.
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Huso, David L.
    Zhou, Shibin
    ONCOTARGET, 2010, 1 (05) : 339 - 348
  • [46] PI3K inhibitors in haematological malignancies
    Benjamin, David J.
    Prasad, Vinay
    LANCET ONCOLOGY, 2022, 23 (08): : E362 - E363
  • [47] The development of inhibitors of PI3K and Akt
    Dennis, PA
    ANNALS OF ONCOLOGY, 2006, 17 : 24 - 24
  • [48] Clinical development of inhibitors of the PI3K
    Saura Manich, C.
    CANCER RESEARCH, 2019, 79 (04)
  • [49] LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family
    Chiosis, G
    Rosen, N
    Sepp-Lorenzino, L
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (07) : 909 - 913
  • [50] Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor
    Hamajima, Toshihiro
    Takahashi, Fumie
    Kato, Koji
    Sugano, Yukihito
    Yamaki, Susumu
    Moritomo, Ayako
    Kubo, Satoshi
    Nakamura, Koji
    Yamagami, Kaoru
    Hamakawa, Nozomu
    Yokoo, Koji
    Fukahori, Hidehiko
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (14) : 3917 - 3924